Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

Mark A. Socinski, MD
Published: Tuesday, Feb 07, 2017



Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

In January 2017, both Bristol-Myers Squibb (BMS) an AstraZeneca have announced separate delays in development of PD-1 and CTLA-4 inhibitor combinations for first-line therapy. BMS stated that it would not be pursuing accelerated approval for nivolumab (Opdivo) and ipilimumab (Yervoy). AstraZeneca anticipates progression-free survival (PFS) data in the durvalumab plus tremelimumab combination will be delayed until mid-2017 and overall survival (OS) findings until 2018.

According to Socinski, this is a sort of "warning shot"—as the over-excitement for these combinations may have overshadowed issues of toxicity or efficacy in phase III trials.
 


Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

In January 2017, both Bristol-Myers Squibb (BMS) an AstraZeneca have announced separate delays in development of PD-1 and CTLA-4 inhibitor combinations for first-line therapy. BMS stated that it would not be pursuing accelerated approval for nivolumab (Opdivo) and ipilimumab (Yervoy). AstraZeneca anticipates progression-free survival (PFS) data in the durvalumab plus tremelimumab combination will be delayed until mid-2017 and overall survival (OS) findings until 2018.

According to Socinski, this is a sort of "warning shot"—as the over-excitement for these combinations may have overshadowed issues of toxicity or efficacy in phase III trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x